BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HEMOPHILIA A
* Individualized and weekly prophylactic regimens resulted in low single-digit median annualized bleeding rates * 98% of bleeding episodes were controlled with one or two injections of rFVIIIFc * No patients developed inhibitors to rFVIIIFc * The primary efficacy and safety objectives were met and Biogen Idec plans to submit an application to US FDA in first half 2013 Weston, Mass and Stockholm, Sweden - October 31, 2012 - Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced positiveresults from A-LONG, a clinical study that